<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Herpes simplex virus infection of the esophagus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Herpes simplex virus infection of the esophagus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Herpes simplex virus infection of the esophagus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A L Bonis, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Camille N Kotton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Esophagitis is most often caused by noninfectious conditions, such as gastroesophageal reflux disease, whereas esophageal infection occurs predominantly in hosts with impaired immunity resulting from chemotherapy, transplantation, or HIV infection. The most common causes of infectious esophagitis include <em>Candida</em>, cytomegalovirus (CMV), and herpes simplex virus (HSV).</p><p>This topic will address the epidemiology, clinical manifestations, diagnosis, and treatment of HSV esophagitis. Topics on candidal and CMV esophagitis are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2427.html" rel="external">"Esophageal candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3751.html" rel="external">"AIDS-related cytomegalovirus gastrointestinal disease"</a> and  <a class="medical medical_review" href="/z/d/html/2432.html" rel="external">"Oropharyngeal candidiasis in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Herpes simplex virus (HSV) infection of the esophagus is usually observed in patients who are immunocompromised, but can occasionally be seen in patients who are immunocompetent. The vast majority of infections are related to HSV type 1, although HSV-2 has occasionally been reported [<a href="#rid1">1,2</a>]. </p><p>HSV esophagitis may result from reactivation of HSV with spread of virus to the esophageal mucosa by way of the vagus nerve or by direct extension of oral–pharyngeal infection into the esophagus [<a href="#rid3">3</a>]. It may also occur during primary herpes infection; in a cohort study of healthy adults and adolescents with herpes esophagitis, 11 of 25 evaluable cases (44 percent) had primary infection based upon serology [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Immunocompromised hosts</span><span class="headingEndMark"> — </span>HSV esophagitis occurs most frequently in solid organ and bone marrow transplant recipients [<a href="#rid4">4-8</a>]. HSV and cytomegalovirus (CMV) were the most commonly identified pathogens in a study of 21 patients with endoscopically proven esophagitis who had undergone bone marrow transplantation [<a href="#rid9">9</a>]. HSV esophagitis has also been reported in organ transplant recipients in the setting of acute rejection and intensive immunosuppression [<a href="#rid5">5,10</a>]. As an example, in a series of renal transplant recipients at a single institution in Pakistan, 97 patients with esophagitis underwent a biopsy during endoscopy, and esophageal candidiasis, CMV, and herpes virus were found in 33, 8, and 5 patients, respectively [<a href="#rid10">10</a>]. Simultaneous infection with multiple pathogens has also been reported in this population [<a href="#rid11">11,12</a>]. The etiology of the esophagitis is likely to be significantly influenced by the type of prophylaxis the patient is receiving at the time of diagnosis (ie, <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a>, <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a>, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, or other antifungal agents). (See  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation"</a>.)</p><p>HSV is a less common cause of esophagitis in patients with HIV infection than in transplant recipients. In three illustrative reports, esophagitis from HSV-1 infection was identified in only 3 to 5 percent of HIV-infected patients with esophagitis [<a href="#rid9">9,13,14</a>]. In most reports, the most common cause of esophagitis in patients with advanced acquired immunodeficiency syndrome (AIDS) was <em>Candida</em>, whereas the most common viral cause was CMV [<a href="#rid14">14</a>]. Both infections coexist in some patients. However, the incidence of infectious esophagitis from any cause has declined since the introduction of potent antiretroviral therapy. (See  <a class="medical medical_review" href="/z/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection"</a> and  <a class="medical medical_review" href="/z/d/html/2427.html" rel="external">"Esophageal candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents", section on 'Impact of treatment'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Immunocompetent patients</span><span class="headingEndMark"> — </span>Esophagitis due to HSV-1 has been described in otherwise healthy patients in case reports [<a href="#rid1">1,15-24</a>]. In a review of 56 patients (39 men and 17 women), the mean age at presentation was 35 years with cases among men predominating in those under 40 years of age [<a href="#rid1">1</a>]. Cases of HSV-1 esophagitis have also been reported in immunocompetent children [<a href="#rid16">16,17</a>]. HSV-2 is also a rare but reported cause of HSV esophagitis in immunocompetent patients [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients usually present with odynophagia and/or dysphagia [<a href="#rid1">1,12,25</a>]. In one report of 46 patients with herpes simplex esophagitis, odynophagia and dysphagia occurred in 35 and 30 percent, respectively [<a href="#rid12">12</a>]. Fever and retrosternal chest pain can also occur, and in a review of 56 immunocompetent patients, these symptoms were present in about half [<a href="#rid1">1</a>]. These latter symptoms are also a feature of herpes simplex virus (HSV) esophagitis in immunocompromised individuals. Abdominal pain and anorexia can also occur, and in the elderly may be presenting symptoms [<a href="#rid26">26,27</a>].</p><p>Patients with HSV esophagitis can have coexistent herpes labialis, glossitis, or oropharyngeal ulcers [<a href="#rid28">28,29</a>]. Complications that have been described in older case reports include bleeding [<a href="#rid30">30</a>], the development of a tracheoesophageal fistula [<a href="#rid31">31,32</a>], and food impaction [<a href="#rid33">33</a>]. Intractable hiccups in association with HSV esophagitis has also been described [<a href="#rid34">34,35</a>]. A few reports have described an association with eosinophilic esophagitis [<a href="#rid36">36-41</a>].</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of herpes simplex virus (HSV) esophagitis is usually based on endoscopic findings confirmed by histopathological examination of the observed lesions. Suggestive findings may sometimes be seen during a <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> swallow (<a class="graphic graphic_diagnosticimage graphicRef60135" href="/z/d/graphic/60135.html" rel="external">image 1</a>).</p><p>Lesions usually affect the squamous mucosa of the distal esophagus where the earliest manifestation is a vesicle, although this early stage is rarely seen on endoscopy. The lesions coalesce to form ulcers (usually less than 2 cm), frequently with normal-appearing intervening mucosa (<a class="graphic graphic_picture graphicRef83681" href="/z/d/graphic/83681.html" rel="external">picture 1</a>). The ulcers are well circumscribed and have a "volcano-like" appearance, distinguishing them from the ulcers seen in cytomegalovirus (CMV) infection, which tend to be linear or longitudinal and deeper [<a href="#rid4">4,42</a>]. Exudates, plaques, or diffuse erosive esophagitis may also be present [<a href="#rid43">43</a>].</p><p>Biopsies or brushing should be taken from the edge of an ulcer where viral cytopathic effects are most likely to be present. Histologic findings include multinucleated giant cells, with ground-glass nuclei and eosinophilic inclusions (Cowdry type A inclusion bodies) that occupy up to one-half of the nuclear volume (<a class="graphic graphic_picture graphicRef67790" href="/z/d/graphic/67790.html" rel="external">picture 2</a>) [<a href="#rid44">44</a>]. Immunohistochemical stains for HSV glycoproteins may also be helpful [<a href="#rid43">43,45</a>]. In patients who do not respond to <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a>, viral culture of suspicious lesions should be performed during endoscopy, if possible, to confirm the diagnosis and to identify resistant viral isolates.</p><p>Qualitative and quantitative polymerase chain reaction (PCR) testing has been investigated to detect HSV DNA from biopsy samples [<a href="#rid46">46,47</a>]. Efforts are also being made to assess whether determining a tissue viral load using PCR testing could improve specificity and positive predictive values [<a href="#rid47">47</a>]. </p><p class="headingAnchor" id="H7"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis includes other infectious causes of esophagitis (mainly cytomegalovirus [CMV] and <em>Candida</em>). Although <em>Candida</em> is the most common fungal cause of esophagitis, other fungal infections, including cryptococcosis, histoplasmosis, blastomycosis, and aspergillosis have rarely been described [<a href="#rid48">48</a>]. Other pathogens, such as mycobacteria and Nocardia, have occasionally been reported [<a href="#rid48">48,49</a>]. In patients with advanced HIV infection, idiopathic aphthous ulcers have been described in up to one-fourth of patients with esophageal symptoms who did not respond to empiric antifungal therapy [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/2427.html" rel="external">"Esophageal candidiasis in adults"</a>.)</p><p>Other diagnostic considerations include noninfectious causes of esophagitis, particularly pill esophagitis (eg, from <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>), autoimmune inflammatory diseases such as Crohn’s disease or lichen planus, or malignancy [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/2255.html" rel="external">"Pill esophagitis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The management of herpes simplex virus (HSV) esophagitis depends upon the host's underlying immune status.</p><p class="headingAnchor" id="H9"><span class="h2">Immunocompromised hosts</span><span class="headingEndMark"> — </span>Immunocompromised hosts should be treated with a longer duration of therapy than is typically given for less invasive HSV infection (eg, genital HSV). For immunocompromised patients able to take oral medications, the dose of <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> is 400 mg orally (PO) five times a day, renally adjusted if necessary, for 14 to 21 days. This dose is generally effective and has few side effects. The management of those with more severe disease is found below. (See <a class="local">'Treatment of patients with severe odynophagia or dysphagia'</a> below.)</p><p><a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">Famciclovir</a> (500 mg two times daily) or <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">valacyclovir</a> (1 g two times daily) can also be considered in patients able to tolerate oral therapy, although there is limited experience with these drugs in HSV esophagitis. Famciclovir and valacyclovir are considered comparable in potency in the treatment of other HSV infections and have the advantage of decreased pill burden; however, they are generally more expensive than <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a>. (See  <a class="medical medical_review" href="/z/d/html/8338.html" rel="external">"Famciclovir: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/8337.html" rel="external">"Valacyclovir: An overview"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Immunocompetent hosts</span><span class="headingEndMark"> — </span>Spontaneous resolution usually occurs in immunocompetent hosts after one to two weeks, although patients may respond more quickly if treated with a short course of oral <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a>. While there are no trials of acyclovir in immunocompetent patients with HSV-1 esophagitis, case reports of patient with HSV esophagitis [<a href="#rid2">2</a>], and treatment experience with acyclovir in immunocompetent patients with oral and genital herpes suggest therapeutic benefit in hastening resolution of lesions. Symptoms have been reported to respond promptly, and acyclovir has proven safe in immunocompetent patients treated with other herpes infections. In patients who are <strong>not</strong> immunocompromised, we suggest treatment with a short course of oral acyclovir (200 mg PO five times a day or 400 mg PO three times a day for 7 to 10 days) unless symptoms already appear to be abating. Acyclovir is generally well tolerated. (See  <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">"Acyclovir: An overview"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Treatment of patients with severe odynophagia or dysphagia</span><span class="headingEndMark"> — </span>Patients with severe odynophagia may require hospitalization for parenteral antiviral therapy, pain management, and hydration or alimentation. Treatment can include:</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous (IV) <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> (5 mg/kg IV every eight hours for 7 to 14 days) can be administered to those who are unable to swallow. Patients who rapidly improve can be switched to oral therapy to complete their therapeutic course. Shortages of IV acyclovir have occurred. If IV acyclovir is not available, alternative agents must be used. Specific recommendations are presented separately. (See  <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">"Acyclovir: An overview", section on 'If there is an acyclovir shortage'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Swallowed viscous <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> oral topical solution (15 mL of a 2% formulation) with or without an antacid can be tried to relieve pain [<a href="#rid51">51</a>], but in our experience is usually only of modest benefit. About 35 percent of the dose is absorbed; thus ingestion should be limited to no more than 300 mg lidocaine (viscous) per dose for patients weighing greater than 65 kg and 4.5 mg/kg lidocaine (viscous) per dose for patients weighing 65 kg or less, and no more than eight doses per day [<a href="#rid52">52</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Drug-resistant HSV</span><span class="headingEndMark"> — </span>Patients who do not respond to therapy may have virus resistant to <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> resulting from mutations within the thymidine kinase (TK) or, less commonly, the DNA polymerase gene of HSV [<a href="#rid53">53</a>]. Viruses with TK mutations are generally cross-resistant to other drugs in this class, including <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">valacyclovir</a> and <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">famciclovir</a>, but remain susceptible to antiviral agents that act directly on DNA polymerase (eg, <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">foscarnet</a>) [<a href="#rid54">54</a>].</p><p>Most experience with <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> resistance is related to HSV oral mucositis or genital infection. Although rare, acyclovir resistance is more commonly seen in immunocompromised patients, those who have undergone chemotherapy, transplantation, or who have HIV infection [<a href="#rid55">55-57</a>]. Many of these patients will have received multiple courses of acyclovir in the past. Resistant HSV can also arise spontaneously from natural variations within the viral population; this is evident from studies that have demonstrated acyclovir resistance in treatment-naive patients [<a href="#rid56">56</a>]. However, in extensive surveys conducted in the United States and the United Kingdom of immunocompetent hosts, isolation of drug-resistant HSV remains low (approximately 0.1 to 0.7 percent of isolates). Low levels of drug resistance have been attributed to rapid clearing of HSV infection by an intact immune system [<a href="#rid58">58</a>].</p><p>Cases of severe persistent infection with acyclovir-resistant HSV occur rarely and almost exclusively in immunocompromised hosts [<a href="#rid58">58</a>]; in immunocompetent hosts, rare cases of drug-resistant virus have cleared without adverse clinical outcome [<a href="#rid58">58</a>].</p><p>Treatment with <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">foscarnet</a> can be effective for immunosuppressed patients with HSV strains known to be resistant to <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> or for those who do not respond to acyclovir, although foscarnet must be given parenterally and is associated with considerable toxicity [<a href="#rid59">59,60</a>]. (See  <a class="medical medical_review" href="/z/d/html/8288.html" rel="external">"Foscarnet: An overview"</a>.) </p><p>The use of the investigational agent pritelivir, a helicase-primase inhibitor, is being evaluated for the treatment of acyclovir-resistant mucocutaneous HSV in immunocompromised adults [<a href="#rid61">61</a>]. Information about this phase 3 trial can be found at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03073967&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPOzwcbbzOabHozNWFrxVBHtpHMVgyOxmw44U%2BW10zA1xQ%3D%3D&amp;TOPIC_ID=8306" target="_blank">clinicaltrials.gov</a>. </p><p class="headingAnchor" id="H3788750005"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>For immunocompromised patients, antiviral therapy may reduce the risk of developing herpes simplex virus (HSV) esophagitis. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary prophylaxis</strong> – Many transplant patients receive antiviral prophylaxis for a period of time after transplant to reduce the risk of developing disease caused by cytomegalovirus and varicella zoster virus. These agents (eg, <a class="drug drug_general" data-topicid="10058" href="/z/d/drug information/10058.html" rel="external">valganciclovir</a> and <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a>) also reduce the risk of developing clinical disease due to HSV. However, clinicians should be aware that some of the newer antiviral prophylaxis agents, such as <a class="drug drug_general" data-topicid="115632" href="/z/d/drug information/115632.html" rel="external">letermovir</a> or <a class="drug drug_general" data-topicid="134463" href="/z/d/drug information/134463.html" rel="external">maribavir</a>, do not prevent HSV (or varicella-zoster virus), and additional antiviral prophylaxis is required to prevent those infections when these agents are used. (See  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary prophylaxis</strong> – Secondary prophylaxis with <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a>, or a similar agent such as valaciclovir or <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">famciclovir</a>, is reasonable for immunocompromised hosts who had moderate to severe esophagitis and remain at risk for recurrent infection (eg, those being treated for organ rejection). When antiviral therapy is used for secondary prophylaxis, the duration of treatment is usually determined on a case-by-case basis depending upon the patient's degree of immunocompromise and risk of recurrent infection. The duration is typically measured in months; secondary prophylaxis to prevent recurrent HSV esophagitis is almost never administered indefinitely.</p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Herpes simplex virus (HSV) infection of the esophagus is usually observed in patients who are immunocompromised and occurs most frequently in those receiving immunosuppressive agents, such as solid organ and bone marrow transplant recipients. However, it has also been described in otherwise healthy patients. (See <a class="local">'Immunocompetent patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients usually present with odynophagia and dysphagia. Fever, epigastric pain, nausea, vomiting, and heartburn are less frequent. Occasional patients have coexistent herpes labialis or oropharyngeal ulcers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis is usually established with an upper endoscopy. Biopsies or brushing should be taken from the edge of an ulcer where viral cytopathic effects are most likely to be present. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis includes other forms of infectious esophagitis and pill esophagitis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are <strong>not</strong> immunocompromised, we suggest treatment with a short course of oral <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> (200 mg orally [PO] five times a day or 400 mg PO three times a day for 7 to 10 days) unless symptoms already appear to be abating (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Immunocompetent patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are immunocompromised, we recommend antiviral therapy for 14 to 21 days (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">Acyclovir</a> (400 mg PO five times a day) has potent anti-HSV activity and is generally the least expensive agent. <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">Valacyclovir</a> or <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">famciclovir</a> afford less frequent dosing if patient adherence is a concern. Intravenous acyclovir (5 mg/kg IV every eight hours for 7 to 14 days) can be used for those who are unable to swallow. (See <a class="local">'Immunocompromised hosts'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-resistant virus should be suspected in patients who do not respond to antiviral therapy within approximately five to seven days. Viruses with thymidine kinase mutations are generally cross-resistant to other drugs in this class, including <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">valacyclovir</a> and <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">famciclovir</a>, but remain susceptible to antiviral agents that act directly on DNA polymerase (eg, <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">foscarnet</a>). (See <a class="local">'Drug-resistant HSV'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For certain immunocompromised patients (eg, transplant recipients), prophylactic antiviral therapy may reduce the risk of developing HSV esophagitis. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H2855298404"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Dori F Zaleznik, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Canalejo Castrillero E, García Durán F, Cabello N, García Martínez J. Herpes esophagitis in healthy adults and adolescents: report of 3 cases and review of the literature. Medicine (Baltimore) 2010; 89:204.</a></li><li><a class="nounderline abstract_t">Kadayakkara DK, Candelaria A, Kwak YE, Loeser C. Herpes Simplex Virus-2 Esophagitis in a Young Immunocompetent Adult. Case Rep Gastrointest Med 2016; 2016:7603484.</a></li><li><a class="nounderline abstract_t">Corey L, Spear PG. Infections with herpes simplex viruses (2). N Engl J Med 1986; 314:749.</a></li><li><a class="nounderline abstract_t">McBane RD, Gross JB Jr. Herpes esophagitis: clinical syndrome, endoscopic appearance, and diagnosis in 23 patients. Gastrointest Endosc 1991; 37:600.</a></li><li><a class="nounderline abstract_t">Mosimann F, Cuénoud PF, Steinhäuslin F, Wauters JP. Herpes simplex esophagitis after renal transplantation. Transpl Int 1994; 7:79.</a></li><li><a class="nounderline abstract_t">McDonald GB, Sharma P, Hackman RC, et al. Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 1985; 88:1111.</a></li><li><a class="nounderline abstract_t">Kang YN, Oh HK, Chang YC, et al. Systemic herpes simplex virus infection following cadaveric renal transplantation: a case report. Transplant Proc 2006; 38:1346.</a></li><li><a class="nounderline abstract_t">Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24:517.</a></li><li><a class="nounderline abstract_t">Wilcox CM, Schwartz DA, Clark WS. Esophageal ulceration in human immunodeficiency virus infection. Causes, response to therapy, and long-term outcome. Ann Intern Med 1995; 123:143.</a></li><li><a class="nounderline abstract_t">Wadhwa RK, Nazeer A, Rai AA, Luck NH. Role of Endoscopic Findings and Biopsies in Renal Transplant Recipients With Gastrointestinal Complications: A Tertiary Care Experience. Exp Clin Transplant 2018; 16:522.</a></li><li><a class="nounderline abstract_t">Gani I, Kosuru V, Saleem M, Kapoor R. Simultaneous candida albicans and herpes simplex virus type 2 esophagitis in a renal transplant recipient. BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">Hoversten P, Kamboj AK, Wu TT, Katzka DA. Variations in the Clinical Course of Patients with Herpes Simplex Virus Esophagitis Based on Immunocompetence and Presence of Underlying Esophageal Disease. Dig Dis Sci 2019; 64:1893.</a></li><li><a class="nounderline abstract_t">Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. Arch Intern Med 1991; 151:1567.</a></li><li><a class="nounderline abstract_t">Bini EJ, Micale PL, Weinshel EH. Natural history of HIV-associated esophageal disease in the era of protease inhibitor therapy. Dig Dis Sci 2000; 45:1301.</a></li><li><a class="nounderline abstract_t">Ramanathan J, Rammouni M, Baran J Jr, Khatib R. Herpes simplex virus esophagitis in the immunocompetent host: an overview. Am J Gastroenterol 2000; 95:2171.</a></li><li><a class="nounderline abstract_t">Rodrigues F, Brandão N, Duque V, et al. Herpes simplex virus esophagitis in immunocompetent children. J Pediatr Gastroenterol Nutr 2004; 39:560.</a></li><li><a class="nounderline abstract_t">Boersma CC, Borowitz SM. Odynophagia. Clin Pediatr (Phila) 2007; 46:556.</a></li><li><a class="nounderline abstract_t">Nagri S, Hwang R, Anand S, Kurz J. Herpes simplex esophagitis presenting as acute necrotizing esophagitis ("black esophagus") in an immunocompetent patient. Endoscopy 2007; 39 Suppl 1:E169.</a></li><li><a class="nounderline abstract_t">Lee B, Caddy G. A rare cause of dysphagia: herpes simplex esophagitis. World J Gastroenterol 2007; 13:2756.</a></li><li><a class="nounderline abstract_t">Geraci G, Pisello F, Modica G, et al. Herpes simplex esophagitis in immunocompetent host: a case report. Diagn Ther Endosc 2009; 2009:717183.</a></li><li><a class="nounderline abstract_t">Bando T, Matsushita M, Kitano M, Okazaki K. Herpes simplex esophagitis in the elderly. Dig Endosc 2009; 21:205.</a></li><li><a class="nounderline abstract_t">Marinho AV, Bonfim VM, de Alencar LR, et al. Herpetic esophagitis in immunocompetent medical student. Case Rep Infect Dis 2014; 2014:930459.</a></li><li><a class="nounderline abstract_t">Rajasekaran V, Rahaman V, Hou X, Steele RW. HSV Esophagitis in an Immunocompetent 17-Year-Old. Glob Pediatr Health 2021; 8:2333794X211052914.</a></li><li><a class="nounderline abstract_t">Upadhaya Regmi B, Subedi RC, Mandal SK, et al. Herpes simplex esophagitis in an immunocompetent host: a case report. Oxf Med Case Reports 2021; 2021:omab091.</a></li><li><a class="nounderline abstract_t">Généreau T, Lortholary O, Bouchaud O, et al. Herpes simplex esophagitis in patients with AIDS: report of 34 cases. The Cooperative Study Group on Herpetic Esophagitis in HIV Infection. Clin Infect Dis 1996; 22:926.</a></li><li><a class="nounderline abstract_t">Custódio SF, Félix C, Cruz F, Veiga MZ. Herpes simplex virus esophagitis-clinical challenges in the elderly. BMJ Case Rep 2021; 14.</a></li><li><a class="nounderline abstract_t">Antaki N, Aljarad Z, Dabbas H, et al. Epigastric pain associated with herpes esophagitis: case report. BMC Infect Dis 2020; 20:754.</a></li><li><a class="nounderline abstract_t">Baehr PH, McDonald GB. Esophageal infections: risk factors, presentation, diagnosis, and treatment. Gastroenterology 1994; 106:509.</a></li><li><a class="nounderline abstract_t">Asano N, Kano Y, Takarada C. Glossitis and esophagitis from herpes simplex virus type 1 infection. CMAJ 2021; 193:E1921.</a></li><li><a class="nounderline abstract_t">Rattner HM, Cooper DJ, Zaman MB. Severe bleeding from herpes esophagitis. Am J Gastroenterol 1985; 80:523.</a></li><li><a class="nounderline abstract_t">Obrecht WF Jr, Richter JE, Olympio GA, Gelfand DW. Tracheoesophageal fistula: a serious complication of infectious esophagitis. Gastroenterology 1984; 87:1174.</a></li><li><a class="nounderline abstract_t">Cirillo NW, Lyon DT, Schuller AM. Tracheoesophageal fistula complicating herpes esophagitis in AIDS. Am J Gastroenterol 1993; 88:587.</a></li><li><a class="nounderline abstract_t">Marshall JB, Smart JR 3rd, Elmer C, et al. Herpes esophagitis causing an unsuspected esophageal food bolus impaction in an institutionalized patient. J Clin Gastroenterol 1992; 15:179.</a></li><li><a class="nounderline abstract_t">Mulhall BP, Nelson B, Rogers L, Wong RK. Herpetic esophagitis and intractable hiccups (singultus) in an immunocompetent patient. Gastrointest Endosc 2003; 57:796.</a></li><li><a class="nounderline abstract_t">Harris J, Smith T, Preis J. Intractable hiccups due to herpetic esophagitis in an immunocompromised patient. IDCases 2016; 4:34.</a></li><li><a class="nounderline abstract_t">Zimmermann D, Criblez DH, Dellon ES, et al. Acute Herpes Simplex Viral Esophagitis Occurring in 5 Immunocompetent Individuals With Eosinophilic Esophagitis. ACG Case Rep J 2016; 3:165.</a></li><li><a class="nounderline abstract_t">Fritz J, Lerner D, Suchi M. Herpes Simplex Virus Esophagitis in Immunocompetent Children: A Harbinger of Eosinophilic Esophagitis? J Pediatr Gastroenterol Nutr 2018; 66:609.</a></li><li><a class="nounderline abstract_t">Cristoforo TA, Rietsma K, Wilsey A, et al. Herpes Esophagitis With Concomitant Eosinophilic Esophagitis in a Child: A Case Report. Clin Pediatr (Phila) 2018; 57:618.</a></li><li><a class="nounderline abstract_t">Bustamante Robles KY, Burgos García A, Suárez Ferrer C. Eosinophilic esophagitis and herpetic esophagitis: cause or consequence? Rev Esp Enferm Dig 2017; 109:393.</a></li><li><a class="nounderline abstract_t">Wichelmann TA, Hoff RT, Silas DN. Acute Herpes Simplex Esophagitis in an Immunocompetent Adult with Eosinophilic Esophagitis. Case Rep Gastroenterol 2021; 15:1003.</a></li><li><a class="nounderline abstract_t">Marella HK, Kothadia JP, Saleem N, et al. A Patient with Eosinophilic Esophagitis and Herpes Simplex Esophagitis: A Case Report and Literature Review. Case Rep Gastrointest Med 2021; 2021:5519635.</a></li><li><a class="nounderline abstract_t">Levine MS. Radiology of esophagitis: a pattern approach. Radiology 1991; 179:1.</a></li><li><a class="nounderline abstract_t">Wong RC, Abdul-Karim FW. Atypical herpes simplex esophagitis. Gastrointest Endosc 2005; 61:291.</a></li><li><a class="nounderline abstract_t">Wilcox CM, Rodgers W, Lazenby A. Prospective comparison of brush cytology, viral culture, and histology for the diagnosis of ulcerative esophagitis in AIDS. Clin Gastroenterol Hepatol 2004; 2:564.</a></li><li><a class="nounderline abstract_t">Desai N, Albahra S, Lucas E, et al. Clinical and Histopathologic Features Can Help Target Immunohistochemical Stain Use in the Diagnosis of Viral Esophagitis. Appl Immunohistochem Mol Morphol 2021; 29:713.</a></li><li><a class="nounderline abstract_t">Dekeyser S, El Nady M, Diaz E, et al. [Diagnosis of herpetic esophagitis in the immunocompetent subject by PCR (Herpès Consensus Générique-Argène). Report of six cases]. Pathol Biol (Paris) 2009; 57:101.</a></li><li><a class="nounderline abstract_t">Jazeron JF, Barbe C, Frobert E, et al. Virological diagnosis of herpes simplex virus 1 esophagitis by quantitative real-time PCR assay. J Clin Microbiol 2012; 50:948.</a></li><li><a class="nounderline abstract_t">Sutton FM, Graham DY, Goodgame RW. Infectious esophagitis. Gastrointest Endosc Clin N Am 1994; 4:713.</a></li><li><a class="nounderline abstract_t">El-Serag HB, Johnston DE. Mycobacterium avium complex esophagitis. Am J Gastroenterol 1997; 92:1561.</a></li><li><a class="nounderline abstract_t">Lee MH, Lubner MG, Peebles JK, et al. Clinical, Imaging, and Pathologic Features of Conditions with Combined Esophageal and Cutaneous Manifestations. Radiographics 2019; 39:1411.</a></li><li><a class="nounderline abstract_t">Shortsleeve MJ, Levine MS. Herpes esophagitis in otherwise healthy patients: clinical and radiographic findings. Radiology 1992; 182:859.</a></li><li class="breakAll">USP-FDA package insert (adult dosing section). http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=4124&amp;type=display (Accessed on August 12, 2008).</li><li><a class="nounderline abstract_t">Frobert E, Ooka T, Cortay JC, et al. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob Agents Chemother 2005; 49:1055.</a></li><li><a class="nounderline abstract_t">Pelosi E, Mulamba GB, Coen DM. Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants. Antiviral Res 1998; 37:17.</a></li><li><a class="nounderline abstract_t">Malvy D, Treilhaud M, Bouée S, et al. A retrospective, case-control study of acyclovir resistance in herpes simplex virus. Clin Infect Dis 2005; 41:320.</a></li><li><a class="nounderline abstract_t">Kriesel JD, Spruance SL, Prichard M, et al. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis 2005; 192:156.</a></li><li><a class="nounderline abstract_t">Stránská R, Schuurman R, Nienhuis E, et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 2005; 32:7.</a></li><li><a class="nounderline abstract_t">Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004; 39 Suppl 5:S248.</a></li><li><a class="nounderline abstract_t">Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320:293.</a></li><li><a class="nounderline abstract_t">Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989; 320:297.</a></li><li><a class="nounderline abstract_t">Cannon L, Tholouli E, Ward C, et al. Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2. Int J STD AIDS 2021; 32:978.</a></li></ol></div><div id="topicVersionRevision">Topic 8306 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20616659" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Herpes esophagitis in healthy adults and adolescents: report of 3 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27195158" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Herpes Simplex Virus-2 Esophagitis in a Young Immunocompetent Adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3005859" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Infections with herpes simplex viruses (2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1756917" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Herpes esophagitis: clinical syndrome, endoscopic appearance, and diagnosis in 23 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8179807" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Herpes simplex esophagitis after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2984077" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Esophageal infections in immunosuppressed patients after marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16797299" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Systemic herpes simplex virus infection following cadaveric renal transplantation: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15896747" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7778827" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Esophageal ulceration in human immunodeficiency virus infection. Causes, response to therapy, and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29534657" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Role of Endoscopic Findings and Biopsies in Renal Transplant Recipients With Gastrointestinal Complications: A Tertiary Care Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31420434" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Simultaneous candida albicans and herpes simplex virus type 2 esophagitis in a renal transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30725296" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Variations in the Clinical Course of Patients with Herpes Simplex Virus Esophagitis Based on Immunocompetence and Presence of Underlying Esophageal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1651690" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10961707" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Natural history of HIV-associated esophageal disease in the era of protease inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007213" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Herpes simplex virus esophagitis in the immunocompetent host: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572901" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Herpes simplex virus esophagitis in immunocompetent children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17579111" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Odynophagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17614059" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Herpes simplex esophagitis presenting as acute necrotizing esophagitis ("black esophagus") in an immunocompetent patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17569149" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A rare cause of dysphagia: herpes simplex esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19750238" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Herpes simplex esophagitis in immunocompetent host: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19691772" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Herpes simplex esophagitis in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24707416" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Herpetic esophagitis in immunocompetent medical student.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34841008" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : HSV Esophagitis in an Immunocompetent 17-Year-Old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34729190" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Herpes simplex esophagitis in an immunocompetent host: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8783688" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Herpes simplex esophagitis in patients with AIDS: report of 34 cases. The Cooperative Study Group on Herpetic Esophagitis in HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33827878" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Herpes simplex virus esophagitis-clinical challenges in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33054791" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Epigastric pain associated with herpes esophagitis: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7980741" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Esophageal infections: risk factors, presentation, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34930768" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Glossitis and esophagitis from herpes simplex virus type 1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3874539" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Severe bleeding from herpes esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6592123" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tracheoesophageal fistula: a serious complication of infectious esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8470643" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Tracheoesophageal fistula complicating herpes esophagitis in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1328357" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Herpes esophagitis causing an unsuspected esophageal food bolus impaction in an institutionalized patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12739568" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Herpetic esophagitis and intractable hiccups (singultus) in an immunocompetent patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27077025" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intractable hiccups due to herpetic esophagitis in an immunocompromised patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144193" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acute Herpes Simplex Viral Esophagitis Occurring in 5 Immunocompetent Individuals With Eosinophilic Esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28937540" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Herpes Simplex Virus Esophagitis in Immunocompetent Children: A Harbinger of Eosinophilic Esophagitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28884583" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Herpes Esophagitis With Concomitant Eosinophilic Esophagitis in a Child: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28247772" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Eosinophilic esophagitis and herpetic esophagitis: cause or consequence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35110988" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acute Herpes Simplex Esophagitis in an Immunocompetent Adult with Eosinophilic Esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34123440" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A Patient with Eosinophilic Esophagitis and Herpes Simplex Esophagitis: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2006257" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Radiology of esophagitis: a pattern approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729246" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Atypical herpes simplex esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15224280" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prospective comparison of brush cytology, viral culture, and histology for the diagnosis of ulcerative esophagitis in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34369420" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical and Histopathologic Features Can Help Target Immunohistochemical Stain Use in the Diagnosis of Viral Esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18842356" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : [Diagnosis of herpetic esophagitis in the immunocompetent subject by PCR (Herpès Consensus Générique-Argène). Report of six cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22170921" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Virological diagnosis of herpes simplex virus 1 esophagitis by quantitative real-time PCR assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7812643" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Infectious esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9317090" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mycobacterium avium complex esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31419189" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical, Imaging, and Pathologic Features of Conditions with Combined Esophageal and Cutaneous Manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1535908" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Herpes esophagitis in otherwise healthy patients: clinical and radiographic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1535908" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Herpes esophagitis in otherwise healthy patients: clinical and radiographic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728902" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9497069" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007528" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A retrospective, case-control study of acyclovir resistance in herpes simplex virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15942905" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Recurrent antiviral-resistant genital herpes in an immunocompetent patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572000" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494896" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2536136" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2536137" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33947276" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
